Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a “real world” STEMI population: results from the Italian “CARDIO-STEMI SANREMO” registry

BACKGROUND: The PEGASUS-TIMI 54 trial inclusion criteria effectively identified high-risk patients with recent myocardial infarction (MI) who would benefit from continuing dual antiplatelet therapy (DAPT) with ticagrelor for more than 12 months. It is unknown how many real-world patients meet these...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanchez, Federico, Boasi, Valentina, Vercellino, Matteo, Tacchi, Chiara, Cannarile, Pierpaolo, Pingelli, Nicoletta, Perri, Dino, Gomez, Laura, Cattunar, Stefano, Mascelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977291/
https://www.ncbi.nlm.nih.gov/pubmed/33736607
http://dx.doi.org/10.1186/s12872-020-01780-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977291/
https://www.ncbi.nlm.nih.gov/pubmed/33736607
http://dx.doi.org/10.1186/s12872-020-01780-y

Ejemplares similares